Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice

Selective sodium glucose cotransporter-2 inhibitor (SGLT2i) treatment promotes urinary glucose excretion, thereby reducing blood glucose as well as body weight. However, only limited body weight reductions are achieved with SGLT2i treatment. Hyperphagia is reportedly one of the causes of this limite...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiba, Yumiko, Yamada, Tetsuya, Tsukita, Sohei, Takahashi, Kei, Munakata, Yuichiro, Shirai, Yuta, Kodama, Shinjiro, Asai, Yoichiro, Sugisawa, Takashi, Uno, Kenji, Sawada, Shojiro, Imai, Junta, Nakamura, Kazuhiro, Katagiri, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786146/
https://www.ncbi.nlm.nih.gov/pubmed/26963613
http://dx.doi.org/10.1371/journal.pone.0150756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786146/
https://www.ncbi.nlm.nih.gov/pubmed/26963613
http://dx.doi.org/10.1371/journal.pone.0150756

Ejemplares similares